Shanghai Bintie Biotechnology Co., Ltd. develops T-cell receptor (TCR) therapies that target solid tumors, specifically focusing on recurrent and refractory malignancies like pancreatic cancer. By identifying shared gene mutations and tumor neoantigens, the company aims to enhance the effectiveness and accessibility of cell therapies while reducing preparation times.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors, particularly recurrent and refractory malignancies like pancreatic cancer, pose significant challenges due to limited effective treatment options. Traditional approaches often struggle to provide long-lasting responses, and the development of personalized cell therapies can be time-consuming and complex.
Solution
Shanghai Bintie Biotechnology is developing T-cell receptor (TCR) therapies designed to target solid tumors by focusing on shared gene mutations and tumor neoantigens. Their approach aims to enhance the efficacy and accessibility of cell therapies, offering a potential solution for patients with late-stage cancers, including pancreatic, colorectal, and lung cancers. By identifying common targets across tumors, Bintie seeks to create treatments that combine personalized and universal elements, reducing preparation times and improving patient outcomes. The company's therapies are designed to provide low-toxicity, long-lasting treatment options for patients with advanced cancers.
Target Audience
The primary target audience includes patients with recurrent and refractory solid tumors, such as pancreatic cancer, colorectal cancer, and lung cancer, as well as the medical professionals who treat them.
Features
- Focus on T-cell receptor (TCR) therapies targeting solid tumors.
- Identification of shared gene mutations and tumor neoantigens as therapeutic targets.
- Development of immunocyte preparations designed for recurrent and refractory malignancies.
- Aims to combine personalized and universal approaches in cell therapy product development.
- Streamlined cell therapy product preparation cycle to reduce treatment time.